OncLive's extensive roster of Strategic Alliance partners continues to expand, as the company and UCLA's Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate on projects that promote groundbreaking cancer research, OncLive announced today. With the new collaboration, OncLive's editorial and marketing groups will help spread the news about the center's leading-edge cancer research, robust clinical enterprise and partnerships with the research industry and local communities.
PLAINSBORO, N.J. — (July 30, 2015) — OncLive®’s extensive roster of Strategic Alliance partners continues to expand, as the company and UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate on projects that promote groundbreaking cancer research, OncLive announced today. With the new collaboration, OncLive’s editorial and marketing groups will help spread the news about the center’s leading-edge cancer research, robust clinical enterprise and partnerships with the research industry and local communities.
One of only 41 centers nationwide designated with the gold-star “comprehensive” status by the National Cancer Institute, the Jonsson Cancer Center has gained an international reputation for taking leading-edge laboratory research and translating it into new and more effective treatments in the clinic. Each year, JCCC physicians handle over 20,000 patient visits and conduct hundreds of clinical trials facilitated at UCLA and through a partnership with TRIO (Translational Research in Oncology), allowing patients nationwide to take part in these pioneering programs.
The Center’s quest to find new and more effective therapies has resulted in a notable number of cancer firsts. In a historic year for the center, UCLA researchers have pioneered three therapies recently approved by the U.S. Food & Drug Administration, including pembrolizumab for melanoma, ramucirumab for lung cancer and palbociclib for breast cancer. Other pioneering therapies that have been developed based on pre-clinical and clinical research conducted at UCLA include trastuzumab, bevacizumab, palbociclib and imatinib.
With a long tradition of outreach to its Los Angeles community, the Jonsson Cancer Center is a proven leader in health disparities research. The JCCC offers numerous programs that connect patients with physicians, counselors and nontraditional medical professionals to aid in the important aspects of cancer care that often occur outside our clinics and hospitals. Among the many JCCC programs and partnerships are the UCLA-LIVESTRONG Survivorship Center of Excellence, Simms/Mann-UCLA Center for Integrative Oncology, Avon Cares for Life and Athena Breast Health Network.
“This combination of community partnerships and important research place UCLA Jonsson Comprehensive Cancer Center at the forefront of the fight against cancer,” said Mike Hennessy Jr., president of Intellisphere Oncology and Healthcare Specialty Group, part of the Plainsboro, N.J.-based Michael J. Hennessy Associates, Inc. (MJH) family of businesses. “We can’t wait to let our readers know about all the latest developments from UCLA in those and other areas.”
“We are proud of the international reputation that the Jonsson Comprehensive Cancer Center has established for developing leading-edge experimental treatments, and our world-renowned scientists will continue to work hard to pioneer new and better ways to diagnose, treat and prevent cancer,” said JCCC Director of Communications Peter M. Bracke. “We are tremendously excited to partner with OncLive to share and publicize our groundbreaking research, therapeutic discoveries and community outreach efforts.”
The UCLA Jonsson Comprehensive Cancer Center joins more than 50 other leading cancer centers, nursing schools and physician groups around the country in partnering with OncLive.
Hennessy added, “Our overarching goal is to succeed in the fight against cancer. Working with these prestigious partners to share our collective knowledge is one way to help overcome this devastating disease.”
OncLive.com is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News and Contemporary Oncology. OncLive offers oncology professionals resources and information they need to provide the best care for their patients. Intellisphere, LLC, a leading provider of healthcare publishing, research and education, is part of the Michael J. Hennessy Associates, Inc. (MJH) family of businesses, based in Plainsboro, NJ. MJH also includes the acclaimed CURE Media Group, which combines science and humanity to make cancer understandable. Its flagship product is CURETM magazine, the largest consumer publication in the U.S. focused entirely on cancer, reaching cancer patients, cancer centers and advocacy groups. To learn more, please visit www.OncLive.com.
About UCLA’s Jonsson Comprehensive Cancer Center
UCLA's Jonsson Comprehensive Cancer Center has more than 500 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2015, the Jonsson Cancer Center was named among the top 10 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 15 years.
To learn more about the center, visit our website at http://www.cancer.ucla.edu.
For UCLA Jonsson Comprehensive Cancer Center: Reggie Kumar, 310.206.2805, ReggieKumar@mednet.ucla.edu
For OncLive: Becky Taylor, 609.240.6886, email@example.com